| Mast cells and histamine | Lifetime | 3 | AT 1 | 99.85 |
| Urticaria and Related Conditions | Lifetime | 4 | AT 1 | 99.78 |
| Eosinophilic Disorders and Syndromes | Lifetime | 13 | AT 1 | 99.80 |
| Food Allergy and Anaphylaxis Research | Lifetime | 11 | AT 2 | 99.83 |
| Hematological disorders and diagnostics | Lifetime | 16 | AT 1 | 99.52 |
| Acute Myeloid Leukemia Research | Lifetime | 60 | AT 1 | 99.75 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 36 | AT 1 | 99.75 |
| Drug-Induced Adverse Reactions | Lifetime | 15 | AT 1 | 99.36 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 32 | AT 1 | 99.38 |
| Polyamine Metabolism and Applications | Lifetime | 26 | AT 1 | 99.22 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 51 | AT 1 | 99.47 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 160 | AT 3 | 99.51 |
| Asthma and respiratory diseases | Lifetime | 186 | AT 2 | 99.48 |
| melanin and skin pigmentation | Lifetime | 64 | AT 1 | 98.92 |
| Allergic Rhinitis and Sensitization | Lifetime | 167 | AT 6 | 99.23 |
| Blood disorders and treatments | Lifetime | 112 | AT 1 | 98.26 |
| Autoimmune Bullous Skin Diseases | Lifetime | 177 | AT 1 | 98.48 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 942 | AT 7 | 98.56 |
| Protein Degradation and Inhibitors | Lifetime | 550 | AT 4 | 96.12 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 580 | AT 4 | 95.80 |
| Eosinophilic Esophagitis | Lifetime | 957 | AT 6 | 95.83 |
| Veterinary Oncology Research | Lifetime | 576 | AT 6 | 93.36 |
| Mast cells and histamine | 2021-2025 | 2 | AT 1 | 99.71 |
| Food Allergy and Anaphylaxis Research | 2021-2025 | 52 | AT 1 | 98.55 |
| Urticaria and Related Conditions | 2021-2025 | 50 | AT 1 | 97.59 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 65 | AT 1 | 97.08 |
| Acute Myeloid Leukemia Research | 2021-2025 | 295 | AT 1 | 97.35 |
| Asthma and respiratory diseases | 2021-2025 | 601 | AT 4 | 94.46 |
| melanin and skin pigmentation | 2021-2025 | 222 | AT 3 | 86.21 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 357 | AT 3 | 89.21 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 638 | AT 10 | 90.34 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 651 | AT 1 | 88.77 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 749 | AT 7 | 85.41 |
| Polyamine Metabolism and Applications | 2021-2025 | 167 | AT 3 | 81.95 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 909 | AT 3 | 74.79 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 794 | AT 8 | 74.11 |
| Drug-Induced Adverse Reactions | 2021-2025 | 679 | AT 4 | 72.65 |
